Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Standardizing REMS Re-Enrollment Procedures

This article was originally published in The Pink Sheet Daily

Executive Summary

Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.

You may also be interested in...



FDA Plans To Improve REMS Effectiveness With Guidance On Goals And Metrics

The agency cited the forthcoming guidance in response to an HHS Inspector General report that questions the effectiveness of the risk management program.

Could Internet Be Path To Simplifying Participation In REMS?

Suggestions to FDA on improving REMS assessments include providing access to patient and physician surveys through a single website and timing assessments based on product launch, not REMS approval.

Setting the Stage: Qnexa and the Power of REMS

Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel